Tag:
Piramal
Latest Headlines
Latest Headlines
Even some domestic firms rail at India's price control plan
India's plan to again put price controls on the majority of the drugs in the country has become a flash point for companies there as well as Western drugmakers.
CMO capacity expansions mirror market
Biopharma manufacturing and high-potency API production were chief drivers of facility expansions among contract manufacturers this year. Expansion activity on the whole was limited, however,
Pfizer exec: Indian price move would push pharma to 'semi-recession'
Pfizer's ( $PFE ) top official in India isn't happy about the government's recent pharma-related moves. In fact, Managing Director Kewal Handa, who heads up Pfizer India, said the latest push to
Piramal to invest $1.5B in ex-India pharma
Piramal's generics excitement in India was only the first step in becoming a "major player" in global pharma. Chairman Ajay Piramal, fresh off a $650 million investment in Vodafone, now says he
Indian pharma M&A may soon need official OK
Ever since Abbott Laboratories ( $ABT ) snapped up Piramal Healthcare's drug business, the Indian government has been debating restrictions on foreign investment in domestic pharma. After all, that
UN conference names Catalent top CMO
Catalent Pharma of Somerset, NJ, takes the top spot among pharma contract manufacturers in the United Nations Conference on Trade and Development's World Investment Report, 2011. India's Piramal
India's drug biz grows 16.5%, aided by Big Pharma
The Indian pharma industry continued its growth streak with a 16.5 percent upswing in 2010 sales. And IMS Health predicts similar results for 2011, citing improved economic conditions that have
Big Pharma retakes Indian territory
There's a bit of hand-wringing in India now that Abbott Laboratories ( NYSE: ABT ) has agreed to buy Piramal Healthcare's generics business for $3.7 billion. That's because Abbott becomes India's
Abbott captures Piramal in $3.7B deal
Abbott Laboratories ( NYSE: ABT ) just leapfrogged its way to No. 1 in India's drug market. The U.S.-based company agreed to buy the domestic unit of Piramal Healthcare , one of India's big generics
Paper: Sanofi bid for Piramal falters
Sanofi-Aventis' plans to buy a majority stake in India's Piramal Healthcare has fallen through because of a disagreement over valuation, sources familiar with the potential deal told the Economic
